The SHMT1-targeted inhibitor AGF347, a novel pyrrolo [3,2-d] pyrimidine compound, shows anti-tumor efficacy in HCT116 colon cancer, H460 non-small cell lung cancer (NSCLC), and MIA PaCa-2 pancreatic cancer [11]. Here, SHMT1 is linked to neoplasm.